Completed NA INTERVENTIONAL 2-arm NCT04121767

Safety and Efficacy of Edoxaban in Thoracoscopic Ablation

Safety and Efficacy of Edoxaban Versus Warfarin in Patients Undergoing a Thoracoscopic Ablation for Persistent Atrial Fibrillation

Sponsor: Samsung Medical Center

Conditions Anticoagulants and Bleeding Disorders Atrial Fibrillation

Interventions Edoxaban Warfarin

Updated 8 times since 2019 Last updated: Jul 31, 2020 Started: Dec 1, 2017 Primary completion: Jun 30, 2020 Completion: Jul 10, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Anticoagulants and Bleeding Disorders and Atrial Fibrillation, this trial is completed. The trial is conducted by Samsung Medical Center and has accumulated 8 data snapshots since 2017. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Sep 2020 — Jan 2021 [monthly]

Completed NA

Status: Recruiting → Completed

▶ Show 3 earlier versions

Aug 2020 — Sep 2020 [monthly]

Recruiting NA
Apr 2020 — Aug 2020 [monthly]

Recruiting NA
Nov 2019 — Apr 2020 [monthly]

Recruiting NA

First recorded

Dec 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Samsung Medical Center

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea